d3 Medicine Report issue

For profit Phase 1
Founded: Parkville Australia (2015)
Status: Acquired by Certara (2016)

Organization Overview

First Clinical Trial
2018
NCT03414450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

D3 (Drug Discovery and Development) | D3 (Drug Discovery and Development), A*STAR Research Entities

Active Ingredients

Drugs in Phase 1 Trials (2)

dasatinib (sprycel) (1 trial)

etc-1907206 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blast Crisis (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 2